Share This Page
Suppliers and packagers for HYDREA
✉ Email this page to a colleague
HYDREA
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Waylis Therap | HYDREA | hydroxyurea | CAPSULE;ORAL | 016295 | NDA | H2-Pharma LLC | 61269-402-60 | 60 CAPSULE in 1 BOTTLE (61269-402-60) | 2009-06-01 |
| Waylis Therap | HYDREA | hydroxyurea | CAPSULE;ORAL | 016295 | NDA | H2-Pharma LLC | 61269-403-60 | 60 CAPSULE in 1 BOTTLE (61269-403-60) | 2009-06-01 |
| Waylis Therap | HYDREA | hydroxyurea | CAPSULE;ORAL | 016295 | NDA | H2-Pharma LLC | 61269-404-60 | 60 CAPSULE in 1 BOTTLE (61269-404-60) | 2009-06-01 |
| Waylis Therap | HYDREA | hydroxyurea | CAPSULE;ORAL | 016295 | NDA | H2-Pharma LLC | 61269-835-10 | 100 CAPSULE in 1 BOTTLE (61269-835-10) | 2009-06-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: HYDREA (Hydroxyurea)
Introduction
Hydroxyurea, marketed under the brand name HYDREA among others, is a versatile chemotherapeutic agent used primarily to treat various myeloproliferative disorders such as chronic myeloid leukemia, sickle cell anemia, and melanoma. As a critical component in oncological and hematological treatment protocols, the supply chain for HYDREA is vital for healthcare providers worldwide. Understanding the landscape of suppliers—ranging from manufacturers to distributors—is essential for stakeholders involved in procurement, regulatory oversight, and market analysis.
Manufacturers of HYDREA
1. Eli Lilly and Company
Eli Lilly pioneered hydroxyurea's commercial development, producing HYDREA since the 1960s. As a major pharmaceutical innovator, Lilly remains a primary supplier, ensuring broad global availability. The company's manufacturing facilities adhere to stringent Good Manufacturing Practice (GMP) standards, guaranteeing high-quality production.
2. Other Generic Manufacturers
Over the decades, multiple generic pharmaceutical firms have entered the hydroxyurea market, driven by patent expirations and increasing demand. Notable among these are:
-
Sandoz (a Novartis division): Produces generic hydroxyurea tablets, supplying several markets worldwide, including North America and Europe.
-
Teva Pharmaceutical Industries: Offers generic hydroxyurea formulations, often providing cost-effective alternatives, especially in developing countries.
-
Mylan (now part of Viatris): Supplies hydroxyurea in various dosages, supporting large-scale therapeutic needs.
-
Sun Pharmaceutical Industries: An emerging player in producing hydroxyurea generics, expanding access in emerging markets.
3. Biotechnological and Specialty Pharmaceutical Companies
While hydroxyurea is traditionally produced via chemical synthesis, some biotech entities focus on biosimilars or formulations optimized for specific patient populations. However, no biosimilar version of HYDREA has yet been approved or marketed.
Key Raw Material Suppliers
Hydroxyurea's manufacturing hinges on the procurement of high-purity chemical precursors. Major chemical suppliers offering critical intermediates include:
-
BASF: A global leader in specialty chemicals, providing intermediates used in hydroxyurea synthesis.
-
Sigma-Aldrich (Part of Merck Group): Supplies pharmaceutical-grade reagents necessary for hydroxyurea production.
Ensuring supply chain robustness depends on these intermediates' availability, quality, and regulatory compliance.
Distribution and Supply Chain Dynamics
1. Global Distribution Networks
Major pharmaceutical companies leverage extensive distribution channels to ensure HYDREA availability in diverse markets. Eli Lilly's distribution network spans North America, Europe, and select Asian markets. Generic manufacturers partner with local distributors to penetrate regional markets, often leveraging existing pharmaceutical supply ecosystems.
2. Regulatory Considerations
Suppliers must obtain approvals from relevant authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other national agencies. These approvals impact market entry and distribution rights, influencing the availability and pricing of HYDREA.
3. Supply Chain Challenges
-
Manufacturing disruptions: Due to raw material shortages, geopolitical factors, or manufacturing issues can cause supply gaps.
-
Pricing pressures: The rise of generics has driven down prices, impacting profitability but enhancing access.
-
Regulatory changes: Evolving standards and licensing requirements influence supplier strategies and market presence.
Regional Supplier Landscape
North America
Eli Lilly remains the predominant supplier, with extensive distribution within the U.S. and Canada. Generic manufacturers such as Teva and Mylan also serve the region, providing competitively priced options.
Europe
European supply features both Eli Lilly’s branded hydroxyurea and multiple generics. Regulatory harmonization via the EMA facilitates market entry for generics, increasing supply options.
Asia-Pacific
Growing demand for hydroxyurea, particularly in India and China, has led to increased local manufacturing. Companies like Sun Pharma and Cipla are expanding production capacities to meet regional needs.
Emerging Markets
In Africa and South America, local generic manufacturers dominate, often sourcing raw materials from global chemical suppliers to produce affordable hydroxyurea formulations.
Regulatory and Patent Landscape
Hydroxyurea was initially patented by Eli Lilly, but patent expirations in many jurisdictions have spurred the proliferation of generics, expanding supply sources. Patents in certain countries may still restrict generic manufacturing, influencing regional supply dynamics. Ongoing patent litigation or licensing agreements can also affect supply stability.
Future Supply Trends and Opportunities
-
Biotech Innovation: Although no biosimilars of hydroxyurea exist currently, innovation in formulations or delivery systems could alter the supplier landscape.
-
Supply Chain Resilience: Pandemic-related disruptions have emphasized the need for diversified manufacturing bases and strategic stockpiling.
-
Sustainability and Raw Material Sourcing: Environmental regulations and raw material availability will increasingly influence supplier choices and manufacturing practices.
-
Market Expansion: Growing indications, especially for sickle cell disease in emerging markets, are likely to enhance demand, prompting new supplier encroachments and capacity expansions.
Key Takeaways
-
Dominant Suppliers: Eli Lilly remains the primary supplier of HYDREA globally, with a substantial share in developed markets. Generic manufacturers like Teva, Mylan, and Sun Pharma significantly contribute to regional supplies, especially in cost-sensitive markets.
-
Raw Material Dependency: The production relies heavily on chemical intermediates supplied by established chemical industry leaders such as BASF and Sigma-Aldrich, emphasizing the importance of source diversification.
-
Distribution Complexity: Global supply chains are influenced by regulatory approvals, patent statuses, and regional market conditions, necessitating strategic sourcing approaches.
-
Market Dynamics: Patent expirations have increased generic competition, improving access and driving down prices but also introducing supply variability concerns.
-
Future Outlook: Innovation, supply chain resilience, and regional demand growth will shape the supplier landscape in coming years.
FAQs
1. Who are the main manufacturers of HYDREA globally?
Eli Lilly remains the primary original manufacturer. Several reputable generic pharmaceutical firms, including Teva, Mylan, and Sun Pharma, also produce hydroxyurea formulations, supporting broad distribution especially in developing markets.
2. What are the key raw material suppliers for hydroxyurea production?
Major chemical suppliers like BASF and Sigma-Aldrich provide essential intermediates used in synthesizing hydroxyurea, ensuring the supply chain's integrity and compliance with pharmaceutical standards.
3. Are there regional differences in hydroxyurea suppliers?
Yes. North American and European markets are predominantly supplied by branded and mature generic manufacturers, while Asia and emerging markets rely more on regional generic firms with local manufacturing capacities.
4. How does patent status influence hydroxyurea supply?
Patent expiration in many jurisdictions has allowed generic manufacturers to enter the market, increasing supply options and reducing prices. However, patent protections in certain regions can limit generic entry, affecting supply diversity.
5. What are the future trends affecting hydroxyurea suppliers?
Potential trends include formulation innovations, increased demand due to expanding clinical indications, efforts to improve supply chain resilience, and regulatory developments that could either facilitate or hinder manufacturing and distribution.
References
- [1] Eli Lilly and Company. Hydroxyurea (HYDREA) product information.
- [2] European Medicines Agency (EMA). Hydroxyurea approvals and biosimilar regulation overview.
- [3] Global pharmaceutical market reports. Trends in generic drug manufacturing and distribution.
- [4] Chemical suppliers (BASF, Sigma-Aldrich). Raw material supply and quality standards for hydroxyurea production.
- [5] Patent litigation and regulatory landscape reports impacting hydroxyurea market.
This analysis provides a comprehensive overview of the current suppliers of HYDREA, emphasizing the importance of diversified sourcing, regulatory adherence, and strategic supply chain management to ensure consistent availability of this critical therapeutic agent.
More… ↓
